Three doctors asked me the same question this year, almost word for word. I have some money set aside. How do I actually put it into a startup?
There are three doors. They cost different amounts, take different amounts of your time, and go wrong in different ways. Let me walk $50,000 through each one.
Door one is the angel check. You wire money straight to the company and get shares. Nobody sits between you and the founder. There are no fees, because there is no middleman to pay. You pick the company yourself, and you live with that pick.
Here is what usually happens. Researchers at Willamette and the University of Washington studied 1,137 angel exits for the Kauffman Foundation. Across all of them, the average was 2.6 times the money in, over about three and a half years. That number hides the real shape. In 52 percent of those exits, the angel got back less than they put in. Seven percent of the exits produced 75 percent of all the money returned.
Real physician voices, twice a week
Free, and one click to unsubscribe.
So the average is fine and the typical result is a loss. Both are true. The average is carried by a handful of huge winners. Correlation Ventures, which has data on thousands of U.S. venture financings, reported in 2023 that 37 percent of invested dollars came back at less than the amount invested, and fewer than 4 percent returned ten times or more.
Put $50,000 into one company and you are buying one ticket in that distribution. AngelList looked at 10,665 investor portfolios on its platform. The median investor holding three or fewer startups had a portfolio worth less than they paid. Investors with more than five holdings had a median annual return of 9.1 percent. Investors with five or fewer had a median of zero.
That is the whole argument for spreading the money out. Not sophistication. Just arithmetic.
Door two is the special-purpose vehicle, or SPV. Plain version: One person finds a deal, sets up a single-purpose company, and a group of people put money into that company, which then buys shares in the startup. One SPV, one startup. You see the specific deal before you commit, which you do not get with a fund.
The costs are public. On AngelList an SPV costs $8,000 to set up plus a $2,000 state filing fee, with no annual fee after that, and total fees capped at 10 percent of what gets raised. Sydecar starts at $4,500. The person running it usually takes carry, meaning a cut of the profits after everyone gets their money back. AngelList says 20 percent is standard. Sydecar reports the average across its own deals is 12 percent.
Minimums vary a lot. AngelList allows checks as small as $1,000. Sydecar says most SPVs set their minimum somewhere between $10,000 and $50,000.
Run the math on $50,000 split across five SPVs at $10,000 each. Say one of them triples. Your $10,000 becomes $30,000, so the profit is $20,000. At 20 percent carry, $4,000 goes to the lead and you keep $26,000. That is the price of not having to find the deal yourself. Whether it is worth it depends entirely on whether that person sees deals you never would.
Door three is a venture fund. You commit money to a manager who invests it across many companies over several years. You do not see the deals in advance. That is the trade: You get spread out automatically, and you give up all control over what gets bought.
Two things make this door hard for a physician with $50,000. The standard terms are a 2 percent annual management fee and 20 percent of profits, which Carta confirmed again across roughly 2,000 U.S. funds in late 2025. And the checks are bigger than people expect. VC Lab reviewed more than 3,400 fund agreements and found the average individual commitment was about $140,000, with three-quarters of commitments under $150,000. Some funds will take $25,000. Most will not.
Now the part nobody mentions until later. Time. The same Kauffman study measured hours. The median angel spent 20 hours checking out a deal before investing. Angels who spent less than 20 hours ended up at 1.1 times their money, with 65 percent of exits below what they put in. Angels who spent more than 20 hours ended up at 5.9 times, with 45 percent below. Above 40 hours it was 7.1 times.
Be careful with that finding. It is a correlation from 2007, not proof. People who spend 40 hours on a deal are usually different from people who spend two, in ways that have nothing to do with hours. Better access. Real expertise in that field. What it does tell you is that door one is a job, not a purchase.
There is also a tax rule worth asking your accountant about. Under Section 1202, stock in a qualifying small company issued after July 4, 2025, can have federal tax on the gain excluded: 50 percent if you hold it three years, 75 percent at four years, and 100 percent at five, up to $15 million per company. The trap is in the fine print for pooled money. If you join a fund or SPV after it already bought the stock, the law says you do not get that break on it. Ask your own tax advisor before assuming anything here. I am not one.
My own path went door one, then door two. I started writing direct checks in 2017, and I learned the diversification problem the way most people do, which is with my own money in too few companies. The move to SPVs was not about sophistication. It was about wanting five or ten shots instead of one, without needing $500,000 to get there.
The short version. One check into one company is a coin flip with worse odds than a coin flip. SPVs let you spread $50,000 across several deals and see each one first, and you pay for that in carry. Funds spread it for you and cost you fees, control, and about a decade of patience.
Pick based on how much time you actually have, not on which one sounds most impressive at a conference. The doctors who do well at this are the ones honest about that from the start.
Harsha Moole is an internal medicine-trained physician-scientist with more than 100 peer-reviewed publications, including work featured in the New England Journal of Medicine. After years of clinical practice and gastroenterology outcomes research, he made an unconventional transition from the bedside to the boardroom by founding PhysicianEstate, a health care-focused venture capital firm.
Over the past seven years, Dr. Moole has made 22 early-stage health care investments across digital health, medical devices, biotech, and therapeutics. He has also built a network of more than 200 physicians from institutions such as Johns Hopkins and Stanford who help source opportunities and provide clinical diligence before capital is deployed. His core thesis is that physician-scientists with firsthand clinical experience are uniquely positioned to identify health care investments that generalist investors often miss.
His research background is reflected in his publication record on Google Scholar, and he shares professional updates on LinkedIn.
